Ashurst advised the sellers on the disposal of Sividon Diagnostics GmbH (Sividon Diagnostics), a leading German breast cancer prognostic test developer, to Myriad Genetics. NASDAQ listed Myriad Genetics is a leader in molecular diagnostics and personalised medicine. Sividon was spun out of Siemens Healthcare Diagnostics in 2010 as part of a management buyout.

The purchase price amounts to up to €50 million (including earn-out).

The Ashurst team was led by partner Alexander Ballmann (Munich) who was supported by counsel Dr Philip Cavaillès (Frankfurt) and associate Friederike Wittmann (Munich; all corporate) as well as by senior associate Juditha von der Heydt (employment, Frankfurt) and partner Heiko Penndorf (tax, Frankfurt).